Olivier Elemento
Olivier Elemento has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, succeeding Mark Rubin, the institute's founding director. Elemento was most recently director of the institute's computational biology group. He is also the associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine and co-leader of the Genetics, Epigenetics, and Systems Biology program in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. He holds a bachelor's degree in mechanical engineering from University Paul Sabatier, a master's degree in mechanical engineering from INSA Toulouse, and a doctorate in computational biology from the University of Montpellier/CNRS.
Andrew Witty
Synthego announced that it has appointed Sir Andrew Witty to its advisory board. Witty is the former CEO of GlaxoSmithKline, where he also served on the board of directors from 2008 to April 2017. He currently serves as a director at UnitedHealth Group and chancellor of the University of Nottingham. Witty has more than 30 years of biopharma experience ranging from product management and business development, to strategic partnerships, including significant international experience serving in a number of senior roles in Europe and Asia while at GSK.
Michael Korn
Michael Korn has been appointed the chief medical officer of Caris Life Sciences, where he will guide the firm's research efforts and clinical strategies for the Adapt Biotargeting System and Caris Molecular Intelligence tumor profiling. Korn is a professor of medicine in the division of hematology/concology at the University of California, San Francisco, and he replaces John Marshal, who was CMO for Caris on a part-time basis. Marshall will continue as chairman of the Precision Oncology Alliance, which is powered by Caris.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.